PER-049-16已完成未知
A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF OFATUMUMAB VERSUS TERIFLUNOMIDE IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS.
OVARTIS BIOSCIENSES PERU S.A.,0 个研究点目标入组 8 人开始时间: 2017年5月10日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Written informed consent.
- •2. Male or female patients aged 18 to 55 years (inclusive) at Screening
- •3. Diagnosis of MS according to the 2010 Revised McDonald criteria
- •4. Relapsing MS: relapsing-remitting course (RRMS), or secondary progressive (SPMS) course with disease activity
- •5. Disability status at Screening with an EDSS score of 0 to 5.5 (inclusive)
- •6. Documentation of at least: 1 relapse during the previous 1 year OR 2 relapses during the previous 2 years prior to Screening OR a positive Gd-enhancing MRI scan during the year prior to randomization (Note: Screening MRI scan may be used if no positive Gd-enhancing scan exist from prior year).
- •7. Neurologically stable within 1 month prior to randomization.
排除标准
- •1. Patients suspected of not being able or willing to cooperate or comply with study protocol requirements in the opinion of the Investigator.
- •2. Patients with primary progressive MS or SPMS without disease activity.
- •3. Patients meeting criteria for neuromyelitis optica.
- •4. Disease duration of more than 10 years in patients with EDSS score of 2 or less.
- •5. Pregnant or nursing (lactating) women.
- •6. Women of child-bearing potential, unless they are using highly effective methods of contraception.
- •7. Sexually active males, unless they agree to use a condom during active treatment.
- •8. Patients with an active chronic disease of the immune system other than MS or with immunodeficiency syndrome.
- •9. Patients with active systemic bacterial, viral or fungal infections, or known to have AIDS or to test positive for HIV antibody at Screening.
- •10. Patients with neurological findings consistent with PML or confirmed PML.
- •11. Patients at risk of developing or having reactivation of syphilis or tuberculosis.
- •12. Patients at risk of developing or having reactivation of hepatitis.
- •13. Have received any live or live-attenuated vaccines within 2 months prior to randomization.
- •14. Have been treated with medications as specified or within timeframes specified (e.g. corticosteroids, ofatumumab, rituximab, ocrelizumab, alemtuzumab, natalizumab, cyclophosphamide, teriflunomide, leflunomide, etc.).
- •15. Patients currently treated with or needing treatment with cholestyramine (unless for accelerated teriflunomide elimination) or leflunomide during the study.
- •16. Use of other investigational drugs at the time of Screening or within the prior 30 days, or five elimination half-lives, or until the expected pharmacodynamic effect has returned to baseline, whichever is longer.
- •17. History of malignancy of any organ system (other than basal cell carcinoma, in situ squamous cell carcinoma of skin, or in situ carcinoma of cervix of the uterus that have been radically treated), within the past 5 years, regardless of whether or not there is evidence of local recurrence or metastases.
- •18. Any of the following conditions or treatments that may impact the safety of the patient:
- •History of, or current, significant cardiac disease including cardiac failure, myocardial, unstable angina, transient ischemic attack, stroke, cardiac arrhythmias requiring treatment or uncontrolled arterial hypertension
- •Concomitant clinically significant cardiac arrhythmias on Screening electrocardiogram.
- •History of familial long QT syndrome or known family history of Torsades de Pointe.
- •History of or active severe respiratory disease.
- •Patients with asthma requiring regular treatment with oral steroids.
- •Severe hepatic impairment (Child-Pugh class C) or any chronic liver or biliary disease.
- •Patients with severe renal impairment.
- •Any medically unstable condition as determined by the Investigator.
- •19. Any abnormal laboratory values, according to protocol, and any other clinically significant laboratory assessment as determined by the Investigator prior to randomization.
- •20. Patients with severe hypoproteinaemia.
- •21. Patients with neurologic/psychiatric disorders, as stated in the protocol, prior to randomization.
- •22. Patients unable or unwilling to undergo MRI scans .
- •23. History of hypersensitivity to any of the study drugs or excipients (including lactose intoler
研究者
相似试验
未知
不适用
A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMPARISON TO INTERFERON BETA-1A (REBIF®) IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSISPER-128-11F. Hoffmann La Roche Ltd / Genentech Inc,22
已完成
不适用
A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMPARISON TO INTERFERON BETA-1A (REBIF®) IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSISMultiple sclerosisPER-024-14F. Hoffmann- La Roche, Ltd /Genentech Inc,21
已完成
不适用
O DISPONIBLEPER-070-10GlaxoSmithKline,
招募中
不适用
A RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, PARALLEL GROUP, MULTICENTER 24 TO 52 WEEK VARIABLE LENGTH STUDY TO ASSESS THE EFFICACY AND SAFETY OF BUDESONIDE, GLYCOPYRRONIUM, AND FORMOTEROL FUMARATE METERED DOSE INHALER (MDI) RELATIVE TO BUDESONIDE AND FORMOTEROL FUMARATE MDI AND SYMBICORT®PRESSURIZED MDI IN ADULT AND ADOLESCENT PARTICIPANTS WITH INADEQUATELY CONTROLLED ASTHMA (KALOS)-J459 Asthma, unspecifiedAsthma, unspecifiedJ459PER-096-20AstraZeneca AB,
未知
不适用
A STUDY ASSESSING THE EFFICACY AND SAFETY OF SARILUMAB ADDED TO NON-BIOLOGIC DMARD THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS.-M069M069PER-033-13Sanofi Aventis Recherche & Development,67